Please use this identifier to cite or link to this item: doi:10.22028/D291-36662
Title: The revised GOLD 2017 COPD categorization in relation to comorbidities
Author(s): Kahnert, Kathrin
Alter, Peter
Young, David
Lucke, Tanja
Heinrich, Joachim
Huber, Rudolf M.
Behr, Jürgen
Wacker, Margarethe
Biertz, Frank
Watz, Henrik
Bals, Robert
Welte, Tobias
Wirtz, Hubert
Herth, Felix
Vestbo, Jørgen
Wouters, Emiel F.
Vogelmeier, Claus F.
Jörres, Rudolf A.
Language: English
Title: Respiratory Medicine
Volume: 134
Pages: 79-85
Publisher/Platform: Elsevier
Year of Publication: 2017
Free key words: COPD
GOLD categorization
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Introduction: The COPD classification proposed by the Global Initiative for Obstructive Lung Disease was recently revised, and the A to D grouping is now based on symptoms and exacerbations only. Potential associations with comorbidities have not been assessed so far. Thus the aim of the present study was to determine the relationship between the revised (2017) GOLD groups A-D and major comorbidities. Methods: We used baseline data from the COPD cohort COSYCONET. Comorbidities were identified from patient self-reports and disease-specific medication: gastrointestinal disorders, asthma, sleep apnea, hyperuricemia, hyperlipidemia, diabetes, osteoporosis, mental disorders, heart failure, hypertension, coronary artery disease. The A-D groups were based on either the COPD Assessment Test or the modified Medical Research Council scale. Exacerbations were also categorized as per GOLD recommendations. Results: Data from 2228 patients were analyzed. Using GOLD group A as a reference, group D was associated with nearly all comorbidities, followed by group B and C. When groups A-D were dichotomized as AC vs. BD (symptoms) and AB vs. CD (exacerbations), all comorbidities correlated with symptoms and/or exacerbations. This was true for both mMRC- and CAT-based categorizations. Conclusions: These findings suggest that the recently modified GOLD categorization is clinically relevant beyond being purely an assessment of symptoms and exacerbations. As the A-D groups correlated with the risk of important comorbidities, with some differences in terms of the correlation with symptoms and exacerbations, the findings underline the importance of identifying comorbidities in COPD, particularly in non-responders to therapy who have high symptoms and/or exacerbation rates.
DOI of the first publication: 10.1016/j.rmed.2017.12.003
URL of the first publication:
Link to this record: urn:nbn:de:bsz:291--ds-366623
ISSN: 0954-6111
Date of registration: 6-Jul-2022
Faculty: M - Medizinische Fakultät
Department: M - Innere Medizin
Professorship: M - Prof. Dr. Robert Bals
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
File Description SizeFormat 
1-s2.0-S0954611117304110-main.pdf270,06 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons